Trends in the use of immunotherapy to treat soft tissue sarcoma.
Am J Surg
; : 115794, 2024 Jun 05.
Article
em En
| MEDLINE
| ID: mdl-38879356
ABSTRACT
BACKGROUND:
The role of immune-oncology (IO) therapy in soft tissue sarcoma (STS) is underexplored. This study characterized IO use in STS.METHODS:
This is a retrospective analysis of patients with a soft tissue mass in the National Cancer Database, 2011-2021. Patients were categorized by IO receipt status. Groupwise testing and proportional trend tests were performed with Chi-squared tests. Multivariate logistic regression was performed to assess factors associated with IO receipt.RESULTS:
Of the 103,092 patients with STS, 1935 (1.9 â%) received or were recommended IO therapy. IO use increased 10-fold (0.24 â%-2.5 â% from 2011 to 2021; p â< â0.0001). Patients had higher odds of receiving IO when having higher grade tumors and metastatic disease, and when treated at an academic research center (all p â< â0.001).CONCLUSIONS:
IO use in STS is low but increasing and primarily used in the metastatic setting. Future studies should identify biomarkers of IO response and facilitators for treatment receipt.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
Am J Surg
Ano de publicação:
2024
Tipo de documento:
Article